# Synergistic antitumor efficacy of a decorin-carrying oncolytic adenovirus combined with chemotherapy in pancreatic cancer

**Authors:** Jing Chen, Wei Ping Tian, Xiao Bai Wei, Xi Wei Zhang, Hong Yuan Gao

PMC · DOI: 10.3389/fonc.2026.1702601 · Frontiers in Oncology · 2026-03-17

## TL;DR

A new treatment combining a decorin-carrying oncolytic adenovirus and chemotherapy shows improved antitumor effects in pancreatic cancer.

## Contribution

The study demonstrates a novel combination therapy using a decorin-carrying oncolytic adenovirus and chemotherapy for pancreatic cancer.

## Key findings

- The combination therapy enhanced tumor-killing effects in both in vivo and in vitro experiments.
- OAV-Decorin promoted IFN-γ expression and suppressed TGF-β, improving the tumor-suppressive microenvironment.

## Abstract

Advances in gene engineering technology have led to the increasing clinical application of oncolytic adenovirus-targeted cancer therapy. Previous studies have demonstrated that oncolytic adenoviruses carrying decorin exhibit significant efficacy in inhibiting the growth of solid tumors. Additionally, these viruses have been shown to participate in the assembly of the tumor extracellular matrix (ECM) by expressing decorin in a subcutaneous renal cell carcinoma tumor model, thereby improving the tumor immune microenvironment. Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths worldwide, characterized by its insidious onset, limited treatment options, and poor long-term survival rates. The matrix surrounding pancreatic tumors is believed to be a key mediator of disease progression through its direct effects on cancer cells and indirect effects on the tumor immune microenvironment. In this study, we constructed a subcutaneous tumor model of pancreatic cancer and applied a combination of Decorin-carrying oncolytic adenoviruses and chemotherapy for in vivo and in vitro experiments. The results showed that the combination of the two further enhanced tumor-killing effects. In vivo experiments further confirmed that OAV-Decorin can promote IFN-γ expression, suppress TGF-β expression, improve the tumor-suppressive microenvironment, and ultimately achieve an antitumor effect.

## Linked entities

- **Proteins:** dcn.S (decorin S homeolog), IFNG (interferon gamma), TGFB1 (transforming growth factor beta 1)
- **Diseases:** pancreatic ductal adenocarcinoma (MONDO:0005184), pancreatic cancer (MONDO:0005192)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, DCN (decorin) [NCBI Gene 1634] {aka CSCD, DSPG2, PG40, PGII, PGS2, SLRR1B}
- **Diseases:** pancreatic cancer (MESH:D010190), PDAC (MESH:D021441), renal cell carcinoma tumor (MESH:D002292), cancer (MESH:D009369)
- **Species:** Adenoviridae (family) [taxon 10508]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13035519/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13035519/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC13035519/full.md

---
Source: https://tomesphere.com/paper/PMC13035519